Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them — particularly once market competition makes these drugs more accessible.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lincoff, A. M. et al. N. Engl. J. Med. 389, 2221–2232 (2023).
Ryan, D. H. et al. Nat. Med. https://doi.org/10.1038/s41591-024-02996-7 (2024).
Colhoun, H. M. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03015-5 (2024).
Kivimäki, M. et al. Lancet Diabetes Endocrinol. 10, 253–263 (2022).
Lean, M. E. et al. Lancet. 391, 541–551 (2018).
Kosiborod, M. N. et al. N. Engl. J. Med. 389, 1069–1084 (2023).
Sattar, N. et al. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
Rossing, P. et al. Nephrol. Dial. Transplant. 38, 2041–2051 (2023).
Chang, A. R., Grams, M. E. & Navaneethan, S. D. Kidney Int. Rep. 2, 261–270 (2017).
Yau, K., Dharia, A., Alrowiyti, I. & Cherney, D. Z. I. Kidney Int. Rep. 7, 1463–1476 (2022).
Marx, N., Husain, M., Lehrke, M., Verma, S. & Sattar, N. Circulation. 146, 1882–1894 (2022).
Sattar, N., McMurray, J. J. V., McInnes, I. B., Aroda, V. R. & Lean, M. E. J. Lancet Diabetes Endocrinol. 11, 58–62 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.S. reports consulting/speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novartis, Menarini-Ricerche, Novo Nordisk, Pfizer, Roche Diagnostics and Sanofi, along with grants paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. M.M.Y.L. has received research grants through his institution, the University of Glasgow, from AstraZeneca, Boehringer Ingelheim and Roche Diagnostics and is a member of a trial steering committee for Cytokinetics and of a clinical endpoints committee for Bayer. D.K.M. reports research support for clinical trials leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA and CSL Behring, as well as honoraria for consultancy from Lilly USA, Pfizer, Boehringer Ingelheim, Lexicon, Novo Nordisk, Applied Therapeutics, Altimmune, CSL Behring, Bayer, Intercept and New Amsterdam.
Rights and permissions
About this article
Cite this article
Sattar, N., Lee, M.M.Y. & McGuire, D.K. What the SELECT trial of semaglutide means for clinicians. Nat Med 30, 1830–1831 (2024). https://doi.org/10.1038/s41591-024-03013-7
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-024-03013-7
